SLC5A2 and chronic kidney disease: The benefits of nonsteroidal mineralocorticoid receptor antagonists remain intact in patients with CKD and T2DM, despite the use of other protective medications, such as sodium-glucose cotransporter 2 inhibitors or glucagon-like peptide-1 receptor agonists [23, 24].